| Literature DB >> 32316182 |
Diana Meireles1,2, Rita Pombinho1,2, Filipe Carvalho1,2, Sandra Sousa1,3, Didier Cabanes1,2.
Abstract
The cell wall of Listeria monocytogenes (Lm), a major intracellular foodborne bacterial pathogen, comprises a thick peptidoglycan layer that serves as a scaffold for glycopolymers such as wall teichoic acids (WTAs). WTAs contain non-essential sugar substituents whose absence prevents bacteriophage binding and impacts antigenicity, sensitivity to antimicrobials, and virulence. Here, we demonstrated, for the first time, the triple function of Lm WTA glycosylations in the following: (1) supporting the correct anchoring of major Lm virulence factors at the bacterial surface, namely Ami and InlB; (2) promoting Lm resistance to antimicrobial peptides (AMPs); and (3) decreasing Lm sensitivity to some antibiotics. We showed that while the decoration of WTAs by rhamnose in Lm serovar 1/2a and by galactose in serovar 4b are important for the surface anchoring of Ami and InlB, N-acetylglucosamine in serovar 1/2a and glucose in serovar 4b are dispensable for the surface association of InlB or InlB/Ami. We found that the absence of a single glycosylation only had a slight impact on the sensibility of Lm to AMPs and antibiotics, however the concomitant deficiency of both glycosylations (rhamnose and N-acetylglucosamine in serovar 1/2a, and galactose and glucose in serovar 4b) significantly impaired the Lm capacity to overcome the action of antimicrobials. We propose WTA glycosylation as a broad mechanism used by Lm, not only to properly anchor surface virulence factors, but also to resist AMPs and antibiotics. WTA glycosyltransferases thus emerge as promising drug targets to attenuate the virulence of bacterial pathogens, while increasing their susceptibility to host immune defenses and potentiating the action of antibiotics.Entities:
Keywords: Gram-positive pathogens; antibiotics; antimicrobial peptides; glycosyltransferase; wall teichoic acid glycosylation
Year: 2020 PMID: 32316182 PMCID: PMC7238011 DOI: 10.3390/pathogens9040290
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1Wall teichoic acid (WTA)-glycosylation promotes surface association of Listeria monocytogenes (Lm) virulence factors. Growth curves in standard culture conditions in vitro (brain heart infusion (BHI) at 37 °C, with agitation) of the different mutants compared with the isogenic wild type (WT) strains from (A) Sv1/2a and (C) Sv4b. Data show the optical density values obtained throughout time. Data represent mean ± standard deviation (SD) of three independent experiments. Western blot on extracts of non-covalently cell surface associated and secreted Lm proteins obtained from (B) Sv1/2a WT, WTA-rhamnosylation deficient (ΔrmlT), WTA-acetylglucosylation deficient (Δlmo1079), and deficient for both glycosylations (Δlmo1079ΔrmlT) strains, as well as (D) Sv4b WT, WTA-galactosylation deficient (ΔgttA), WTA-glucosylation deficient (ΔgltB), and deficient for both glycosylations (ΔgttAΔgltB) strains.Lm Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein levels, and Ponceau S (Sv1/2a) and Coomassie Brilliant Blue (Sv4b) staining were used as the loading control. Images are representative of at least three independent experiments.
Figure 2WTA-glycosylation promotes Lm resistance against antimicrobial peptides (AMPs). Quantification of viable Lm strains, (A) Sv1/2a and (C) Sv4b, after incubation of the exponential-phase Lm strains with the antimicrobial peptides cathelicidin-related antimicrobial peptide (CRAMP) and LL-37 (10 μg/mL). Values from the AMP-treated samples were normalized to untreated controls (set at 100). Data represent mean ± SD of at least three independent experiments. Bacterial growth curves of Lm strains (B) Sv1/2a and (D) Sv4b grown in the presence of CRAMP and LL-37 (10 μg/mL). Data represent mean ± SD of three independent experiments (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).
Figure 3WTA-glycosylation promotes Lm-decreased susceptibility to antibiotics. E-test for gentamicin, ampicillin, and benzylpenicillin of Lm strains from (A) Sv1/2a and (B) Sv4b. The respective minimum inhibitory concentrations (MICs) are shown in the tables below the E-test images. Data represent mean ± SD of at least three independent experiments.
Bacterial strains and plasmids used in this study.
| Bacterial Strains and Plasmid | Lab Code | Relevant Characteristics | Source |
|---|---|---|---|
|
| |||
|
| DC 4 | Wild-type; Sv 1/2a | [ |
|
| DC492 | EGD-e | [ |
|
| DC 858 | EGD-e | This study |
|
| DC 899 | EGD-e | This study |
|
| DC 825 | Wild-type; Sv 4b | ATCC®23074 |
|
| DC 826 | WSLC 1042 | [ |
|
| DC 827 | WSLC 1042 | [ |
|
| DC 828 | WSLC 1042 | [ |
|
| |||
|
| Competent cells | Life Technologies | |
|
| |||
|
| DC 48 | Ampr and Eryr | [ |
Primers used to amplify the flanking regions.
| Primers | Sequence (5’ → 3’) * | Restriction | |
|---|---|---|---|
|
| AGTC | BamHI | |
|
| AGTC | SalI | |
|
| AGTC | SalI | |
|
| AGTC | NcoI | |
|
| CGG | SalI | |
|
| CGG | NcoI | |
|
| |||
|
| GCAAATTGGAATGGGAGGCG | ||
|
| GGATGCCTTGTTGCCGAAAC | ||
|
| TATTGCCACACGCTTTACCG | ||
|
| CTTCCACGATTGAACGAACG | ||
|
| GACGGATCCCGCAACTTCGCAAAATGGG | ||
|
|
| AGCGTCGACGTCGCCATACCATCTGTTTG | |
|
| |||
|
| pMAD Fw | TGATGGTCGTCATCTACCTGCC | |
|
| pMAD Rv | CCTACGTAGGATCGATCCGACC | |
* Restriction sites added to the 5’ end of the primer sequence are underlined.
Range of antibiotic concentrations tested against Lm.
| Antibiotic | Strip Concentration (μg/mL) |
|---|---|
|
| 0.016-256 |